Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US
~OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals in the country~ MUMBAI, 19 MAY, 2022 (GPN): – Regrow Biosciences, an Indian-centric global biotech company, is glad…